TITLE

Hope or Hype--Cytokine Therapy in ERCP-Induced Pancreatitis

AUTHOR(S)
O'Loughlin, Colm J.; Karnam, Umaprasanna S.; Barkin, Jamie S.; Johnson, David
PUB. DATE
June 2001
SOURCE
American Journal of Gastroenterology;Jun2001, Vol. 96 Issue 6, p1930
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In a single-center study from Belgium, Deviere et al. reported the use of the anti-inflammatory cytokine interleukin (IL) 10 as prophylaxis against ERCP-induced pancreatitis. One hundred forty-four patients undergoing ERCP were randomized to receive either a placebo (group 0) or a single i.v. injection of 4 µg/kg (group 1) or 20 µg/kg (group 2) of IL-10 in a double-blinded manner. Seven patients were excluded on an intention to treat or per protocol basis. The primary endpoint of the study was the effect of IL-10 on serum hydrolases (amylase and lipase) measured at 4, 24, and 48 h after ERCP. Hyperhydrolasemia was defined as an increase in amylase and/or lipase levels more than three times normal values. The secondary endpoint was to evaluate changes in plasma cytokines (IL-6, IL-8, and tumor necrosis [TNF] serum levels) and the incidence of clinical acute pancreatitis. This was defined as hyperhydrolasemia associated with new or worsened abdominal pain persisting for more than 4 h after ERCP. The three groups were comparable for number of patients (groups 0, 1, and 2 consisted of 45, 48, and 44 patients, respectively) as well as for age, sex, underlying disease, indication for treatment, and baseline plasma levels of C-reactive protein, cytokines, and hydrolases. The authors found no significant difference in serum C-reactive protein, cytokine, and hydrolase plasma levels between the groups after ERCP. Overall, 43 of the 137 study patients developed hyperhydrolasemia. These were distributed as follows: 18 (40%) in group 0, 14 (29%) in group 1, and 11 (25%) in group 2 (p = 0.297, non-significant). Overall, 19 patients (of the entire study population) developed acute clinical pancreatitis and were distributed as follows: 11 (24.4%) in group 0, five (10.4%) in group 1, and three (6.8%) in group 2 (p = 0.038). Two severe cases were observed in the placebo group. Logistic regression identified three independent risk factors for post-ERCP pancreatitis: IL-10 administration (odds ratio [OR] = 0.46, 95% CI = 0.22-0.96, p = 0.039), pancreatic sphincterotomy (OR = 5.04, 95% CI = 1.53-16.61, p = 0.008), and acinarization (OR = 8.19, 95% Cl = 1.83-36.57, p = 0.006). The authors conclude that a single i.v. dose of IL-10 30 min before the procedure independently reduces the frequency of post-ERCP pancreatitis.
ACCESSION #
17637085

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics